Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Science. Author manuscript; available in PMC 2009 November 17.
Published in final edited form as:
PMCID: PMC2778341

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help


The CD8+ cytotoxic T cell response to pathogens is thought to be CD4+ helper T cell independent because infectious agents provide their own inflammatory signals. Mice that lack CD4+ T cells mount a primary CD8 response to Listeria monocytogenes equal to that of wild-type mice and rapidly clear the infection. However, protective memory to a challenge is gradually lost in the former animals. Memory CD8+ T cells from normal mice can respond rapidly, but memory CD8+ T cells that are generated without CD4 help are defective in their ability to respond to secondary encounters with antigen. The results highlight a previously un-described role for CD4 help in promoting protective CD8 memory development.

Dual recognition of antigen, the requirement for two sites to be recognized as foreign, provides a safeguard against autoimmunity. A strong antibody response by B cells depends on the concurrent activation of CD4+ helper T cells. Similarly, the CD8+ T cell response to noninflammatory immunogens, such as antigen-loaded, transformed, or allogeneic cells, also depends on antigen recognition by CD4+ T cells. In contrast, the CD8 response to acute infections with live virus or intracellular bacteria has been classified as CD4 helper independent. This dichotomy has been neatly explained by the idea that antigen-presenting cell (APC) activation is pivotal to the development of strong primary effector CD8+ T cell responses leading also to long-lasting protective memory. Thus, in cases of immunization with antigen from a noninflammatory source, CD4+ T cells are required to activate APCs through CD40 signaling, “licensing” the APC to stimulate a full-blown CD8 response (13). By contrast, infectious agents such as the intracellular Gram-positive pathogen Listeria monocytogenes, which carry a plethora of immunostimulatory signals (such as cell wall components, flagellin, and CpG DNA) (4, 5), activate APCs directly, thereby bypassing the need for CD4 help (6).

We studied the kinetics of bacterial clearance, the expansion and contraction of antigen-specific CD8+ cells, and the acquisition of protective immunity in intact mice and in mice lacking CD4 T cell function. We used tetramers of class I molecules and the ovalbumin peptide to monitor the CD8+ T cell response to a recombinant strain of Listeria that makes chicken ovalbumin, rL-mOva (7). Consistent with previous work (8, 9), both strains cleared the infection within 7 days (Fig. 1A) and developed equally robust primary CD8 responses to the Ova determinant expressed by the recombinant Listeria (Fig. 1C). Unexpectedly, the ability to resist a second challenge dose of Listeria gradually waned in the class II−/− mice (Fig. 1B). This decline was not due to a loss of memory T cells, because tetramer and intracellular cytokine staining after peptide restimulation revealed that CD8+ memory cell numbers were maintained at close to wild-type levels over a 60-day period after primary immunization. At later time points, the numbers of memory T cells declined to less than half those of wild type (Fig. 1C). At the peak of the primary response, the CD8 response and function appeared normal in both sets of mice. The class II−/− animals generated high numbers of Kb/Ova tetramer-positive staining cells, which were able to produce high levels of interferon-γ (IFN-γ) during in vitro stimulation and were able to lyse peptide-coated target cells (Fig. 2, A to D). After secondary challenge with rLmOva, however, there was a marked deficiency in the response of class II−/− mice, as measured by tetramer-positive staining, the number of IFN-γ-positive cells, or levels of cytotoxic activity (Fig. 2). Quantitation of the Ova-specific CD8 T cells showed that the wild-type and mutant mice contained roughly equal numbers of memory cells at day 60 before the second immunization. However, the wild-type numbers increased about 80-fold in the 3 days after secondary immunization, whereas the numbers of Ova-specific CD8+ cells in class II−/− mice increased less than 10-fold (Fig. 2B). In a separate experiment, even at 5 days after secondary immunization, Ova-specific CD8 cells from class II−/− mice expanded to only a third of the number in wild-type mice. This result revealed that, although naïve CD8+ T cells could respond very well to Listeria infection in the absence of CD4+ T cell help, memory CD8+ T cells in the same animals responded poorly. To determine whether wild-type memory CD8 cells become more helper dependent than their naïve counterparts, we depleted Listeria-primed B6 mice of CD4+ cells by injection of an opsonizing CD4 monoclonal antibody 80 days after priming, immediately before secondary immunization. Depleting the CD4 T cells at this late stage after priming had no deleterious effect on the ability of memory CD8 cells in wild-type mice to respond to secondary antigen challenge (Fig. 2E).

Fig. 1
Mice deficientin CD4+ T cells show a progressive loss in protective immunity. (A) Wild-type C57BL/6 and major histocompatibility complex (MHC) class II–deficient (class II−/−) mice were injected intravenously with 2 × 10 ...
Fig. 2
Equivalent primary CD8+ T cell response, but weak secondary response, in MHC class II– deficient mice compared with wild-type mice. Naïve and 60-day PI mice were given 2 × 103 or 105 rLmOva, respectively. Primary CD8+ T cell responses ...

To more rigorously compare the functional properties of memory CD8+ T cells generated in wild-type versus class II−/− mice, we tested the ability of these cells to mount recall responses after adoptive transfer into wild-type hosts. Because the host mice carried an allelic Thy1.1 marker that distinguished their T cells from transferred T cells, the primary response of the naïve host T cells and the secondary response of the transferred memory cells could be simultaneously monitored. Spleen cells from B6 and class II−/− mice that had been primed 80 days previously with rLmOva were depleted of CD4+ cells, and a sample was stained with tetramers and for IFN-γ–producing cells to estimate the frequency of Ova-specific memory cells (Fig. 3A). Equal numbers (104) of wild-type or class II−/− memory CD8+ cells were then adoptively transferred into naïve B6 (Thy1.1×Thy1.2) F1 recipients and challenged with rLmOva. Seven days after immunization, the Ova-specific CD8 response of the mice was assessed by tetramer staining and peptide-stimulated IFN-γ production (Fig. 3B). Naïve B6 (Thy1.1 × Thy1.2) mice that received no adoptively transferred cells showed a typical primary anti-Ova CD8 response. Mice that received 104 wild-type memory cells showed a diminished host response and a large secondary response by the transferred memory cells. In contrast, transferred Ova-specific memory cells derived from the class II−/− mice mounted a much weaker recall response. The slower response of the class II−/− memory cells allowed the naïve (host) T cell response to occur as if there were no competition (Fig. 3B). This provides strong evidence that memory cells generated in the absence of CD4 T cell help during initial priming differ qualitatively from memory cells generated in the presence of normal CD4+ T cell help, resulting in impaired ability to respond to secondary challenge, even if CD4+ T cells are subsequently supplied. Not only were memory CD8 T cells from class II−/− mice less vigorous than wild-type counterparts, they also compared poorly with naïve CD8 T cells (Fig. 3B). It is likely that of 104 injected memory cells, only 10% engraft or “take” in the host, where they compete with an estimated 100 to 200 endogenous, naïve, Ova-specific CD8 T cells (10).

Fig. 3
Memory CD8+ T cells from MHC class II−/− mice show reduced ability to proliferate after transfer into wild-type mice. CD8+ T cells (Thy1.2) from wild-type and class II−/− mice 80 days after priming were enriched with magnetic ...

Other reports have shown the decline of CD8+ T cell memory in mice that lack CD4+ T cells (1119). In these cases, however, the immunogen was a viral infection. Two problems may confound the issue: First, the infection may become chronic in CD4-deficient animals such that T cells would be continually exposed to persisting antigen. In such situations, it is well established that chronically stimulated CD8 cells require CD4 cells for survival (1521). Second, the deficient antiviral antibody response in CD4-deficient mice may play a role in the loss of protection. Conversely, antibody plays no role in Listeria immunity, making this less of a problem in the system used in our study (2224).

A recent study led to the suggestion that CD40L-CD40 interaction between CD4 and CD8 cells responding to a cellular form of antigen [male cells expressing histocompatibility-Y (HY) antigen] is essential for the generation of robust CD8 memory cells (25, 26). CD8 cells initially responded well to antigen in the absence of CD4 help but made a “lethargic” response to a secondary immunization. This finding suggests that injections of activating CD40-specific antibody to replace the requirement for CD4 help during CD8 responses (1, 2) may operate at the level of the APC, the CD8+ cell, or both. It will be important to assess the relevance of direct or indirect CD40 interactions between T cells in the CD8 response to immunogens such as Listeria. How might lethargic CD8 memory cells generated in the absence of help be different from normal memory cells? Are they the same clones that have failed to undergo a complete program of differentiation, or are they a different subset of the polyclonal repertoire resulting from a failure to select for the fittest clones to become memory cells? The study of the anti-HY response used monoclonal CD8 T cells, and we can conclude in this case that the generation of lethargic memory CD8 cells is due to a failure to differentiate properly (25, 26), although both possibilities may apply during a polyclonal, endogenous CD8 response.

Our results imply that vaccination schemes that target only CD8 immunity, even though they may stimulate strong, early responses, will fail to provide long-term protection. Defining all of the signals required to produce long-lived, robust memory cells and understanding how they are maintained will aid vaccine design.

Supplementary Material

Online Materials and Methods


Supporting Online Material

Materials and Methods


References and Notes

1. Bennett SR, et al. Nature. 1998;393:478. [PubMed]
2. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. Nature. 1998;393:480. [PubMed]
3. Ridge JP, Di Rosa F, Matzinger P. Nature. 1998;393:474. [PubMed]
4. Janeway CA, Jr, Medzhitov R. Annu. Rev. Immunol. 2002;20:197. [PubMed]
5. Gordon S. Cell. 2002;111:927. [PubMed]
6. Rahemtulla A, et al. Nature. 1991;353:180. [PubMed]
7. Materials and methods are available as supporting material on Science Online.
8. Lauvau G, et al. Science. 2001;294:1735. [PubMed]
9. Ladel CH, Flesch IE, Arnoldi J, Kaufmann SH. J. Immunol. 1994;153:3116. [PubMed]
10. Blattman JN, et al. J. Exp. Med. 2002;195:657. [PMC free article] [PubMed]
11. von Herrath MG, Yokoyama M, Dockter J, Oldstone MB, Whitton JL. J. Virol. 1996;70:1072. [PMC free article] [PubMed]
12. Belz GT, Wodarz D, Diaz G, Nowak MA, Doherty PC. J. Virol. 2002;76:12388. [PMC free article] [PubMed]
13. Liu H, Andreansky S, Diaz G, Hogg T, Doherty PC. J. Immunol. 2002;168:3477. [PubMed]
14. Riberdy JM, Christensen JP, Branum K, Doherty PC. J. Virol. 2000;74:9762. [PMC free article] [PubMed]
15. Kalams SA, Walker BD. J. Exp. Med. 1998;188:2199. [PMC free article] [PubMed]
16. Battegay M, et al. J. Virol. 1994;68:4700. [PMC free article] [PubMed]
17. Matloubian M, Concepcion RJ, Ahmed R. J. Virol. 1994;68:8056. [PMC free article] [PubMed]
18. Cardin RD, Brooks JW, Sarawar SR, Doherty PC. J. Exp. Med. 1996;184:8056. [PMC free article] [PubMed]
19. Janssen EM, et al. Nature. 2003;421:852. [PubMed]
20. Zajac AJ, et al. J. Exp. Med. 1998;188:2205. [PMC free article] [PubMed]
21. Zajac AJ, Murali-Krishna K, Blattman JN, Ahmed R. Curr. Opin. Immunol. 1998;10:444. [PubMed]
22. Shen H, et al. J. Immunol. 2003;170:1443. [PubMed]
23. Edelson BT, Cossart P, Unanue ER. J. Immunol. 1999;163:4087. [PubMed]
24. Edelson BT, Unanue ER. Curr. Opin. Immunol. 2000;12:425. [PubMed]
25. Bourgeois C, Veiga-Fernandes H, Joret AM, Rocha B, Tanchot C. Eur. J. Immunol. 2002;32:2199. [PubMed]
26. Bourgeois C, Rocha B, Tanchot C. Science. 2002;297:2060. [PubMed]
27. We thank B. Dere for assistance. This work was supported by NIH grant AI 19335 and the Howard Hughes Medical Institute.